Company Events & EarningsExtended setexperimental liveNew
Pdufa Extension Short
Updated dailyData needs: mediumshort only
paper
2011
Source
Kaitin, K.I. & DiMasi, J.A. (2011). "Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009." Drug Information Journal, 45(2-3), 175-186.
Read the paper →
In plain terms
When the FDA pushes back a drug's review date by a month or more, we short the sponsor for the next few weeks.
How it works
FDA PDUFA action-letter delay (Complete Response Letter or 3-month extension) signals additional analyses/trials are required; sponsor stock reprices -3 to -5% event-day with -2% drift over 30d.
No live results for this strategy yet. Charts appear once it has earned a top spot on at least one stock, either on its own or as part of a blend of several strategies.
Loading substrate evidence…
Data dependencies
- Daily prices
Adjusted-close OHLCV for every US-listed ticker; primary price feed.
- Fda adcomm
A data feed this strategy reads, refreshed on its normal schedule.
Expected edge
- Reported return
- -3 to -5% event-day, -2% over 30d
- Tested over
- T+1 to T+20d
Kaitin-DiMasi 2011: -3 to -5% event-day, -2% over 30d.
Example tickers where this is likely to fire
Illustrative only, the signal fires based on the live data, not a fixed list.
Related families
Explore Pdufa Extension Short on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.